As clinical trials generate ever larger and more complex datasets, platform-based approaches offer more efficient solutions.
CEO David Chang emphasized conviction in the company’s allogeneic platform, stating the focus is on “delivering what patients need now” and making “the promise of curative onetime off-the-shelf cell ...
Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company focused on ...
Corvus Pharmaceuticals will present new interim data from its Phase 1 clinical trial for soquelitinib at the prestigious Society for Investigative Dermatology 2025 Annual Meeting, highlighting ...
Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has ...
Corvus Pharmaceuticals, Inc. will release interim data from its Phase 1 clinical trial of soquelitinib for patients with moderate to severe atopic dermatitis on December 18, 2024. The data will be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback